Trends in medication use in patients with type 2 diabetes mellitus: A long-term view of real-world treatment between 2000 and 2015

Diabetes, Metabolic Syndrome and Obesity

Volumn 9, Issue , 2016, Pages 371-380

  Higgins, Victoria ^a   Piercy, James ^a   Roughley, Adam ^a   Milligan, Gary ^a   Leith, Andrea ^a   Siddall, James ^a   Benford, Mike ^a  

^a ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Insulinization; Real world; Treatment trends; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET THERAPY; DRUG USE; EXERCISE; FEMALE; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; PRESCRIPTION; QUESTIONNAIRE; TIME TO TREATMENT; TREND STUDY;

EID: 84995679707     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S120101     Document Type: Article

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
2. National Institute for Health and Care Excellence Guidance [webpage on the Internet]. Type 2 diabetes: the management of type 2 diabetes. Available from: https://www.nice.org.uk/guidance/ng28. Accessed August 18, 2016.
3. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36: 2271–2279.
4. Ali MK, McKeever Bullard K, Imperatore G, Barker L, Gregg EW; Centers for Disease Control and Prevention (CDC). Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes –National Health and Nutrition Examination Survey, United States, 2007–2010. MMWR Morb Mortal Wkly Rep. 2012;61(suppl):32–37.
5. Health and Social Care Information Centre. National Diabetes Audit 2012–2013. Report 1: Care Processes and Treatment Targets; 2014. Available from: http://www.hscic.gov.uk/catalogue/PUB14970/natidiab- audi-12-13-care-proc-rep.pdf. Accessed August 18, 2016.
6. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Realworld physician and patient behaviour across countries: diseasespecific programmes –a means to understand. Curr Med Res Opin. 2008;24:3063–3072.
7. US Department of Health and Human Services. Summary of the HIPAA Privacy Rule; 2003. Available from: http://www.hhs.gov/sites/default/files/privacysummary.pdf. Accessed August 18, 2016.
8. EphMRA Code of Conduct [webpage on the Internet]. Updated January 2016. Available from: http://www.ephmra.org/code-of-conduct/2/APurpose-Scope-and-Sources. Accessed August 18, 2016.
9. Health Information Technology. Health Information Technology Act. Available from: https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf. Accessed August 18, 2016.
10. Silvey M, Higgins V, Leith A, Benford M, Graham A, Piercy J. International differences in the role of payer and administrative controls in prescribing decisions in type 2 diabetes mellitus (T2DM). Value Health. 2016;19:A209.
11. U.S. Food & Drug Administration [webpage on the Internet]. FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia Agency says drug to remain on market, while safety assessment continues; 2007. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109026.htm. Accessed September 13, 2016.
12. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210. [Erratum in: BMJ Open. 2016;6:e010210corr1].
13. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012;14(9):810–820.
14. Saunders C, Byrne CD, Guthrie B, et al; Scottish Diabetes Research Network Epidemiology Group. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30(3):300–308.
15. Hubbard TE, Paradis R. Real-World Evidence: A New Era for Health Care Innovation. The Network for Excellence in Health Innovation; 2015. Available from: http://www.nehi.net/writable/publication_files/ file/rwe_issue_brief_final.pdf. Accessed August 18, 2016.